SRR23303766
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.590
- INFLAMMATORY_RESPONSE+0.470
- ALLOGRAFT_REJECTION+0.450
- IL6_JAK_STAT3_SIGNALING+0.410
- ANGIOGENESIS+0.400
- KRAS_SIGNALING_UP+0.390
- INTERFERON_GAMMA_RESPONSE+0.380
- COMPLEMENT+0.370
- COAGULATION+0.330
- INTERFERON_ALPHA_RESPONSE+0.330
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.580
- MYC_TARGETS_V1-0.450
- ADIPOGENESIS-0.430
- PEROXISOME-0.400
- PROTEIN_SECRETION-0.390
- MYC_TARGETS_V2-0.370
- ESTROGEN_RESPONSE_EARLY-0.350
- NOTCH_SIGNALING-0.340
- DNA_REPAIR-0.300
- FATTY_ACID_METABOLISM-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12202479 | — | — | 0.894 |
| 2 | SRR12475140 | — | — | 0.887 |
| 3 | GSM5359446 | — | — | 0.865 |
| 4 | DRR168603 | — | — | 0.863 |
| 5 | R344 | — | — | 0.863 |
| 6 | MNG276 | — | — | 0.862 |
| 7 | R263 | — | — | 0.849 |
| 8 | MNG1166 | — | — | 0.849 |
| 9 | MNG68 | — | — | 0.848 |
| 10 | DRR168533 | — | — | 0.848 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.590 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.470 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.450 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.410 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.390 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.380 | Idelalisib | — uncovered |
| COMPLEMENT | 0.370 | Inavolisib | — uncovered |
| COAGULATION | 0.330 | Binimetinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.330 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.320 | Inavolisib | — uncovered |
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.250 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.250 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.240 | Cobimetinib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.190 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.180 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.170 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.150 | Inavolisib | — uncovered |